Citigroup Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $42
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $42.
Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $42.